Kezar Life Sciences (KZR) Stock

About Kezar Life Sciences

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences is led by CEO Christopher J. Kirk, employs 55 people, headquartered in US, publicly traded since 2018.

Kezar Life Sciences (KZR) stock trades at $7.29 with a market capitalization of $53.86M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.96, reflecting a net loss over the last twelve months, price-to-book of 0.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.53 and $7.55, and currently trades 3.4% below its 52-week high.

On profitability, Kezar Life Sciences generates a return on equity (ROE) of -80.00% (negative, reflecting a net loss), return on capital employed of -74.29%.

Official website: www.kezarlifesciences.com

Kezar Life Sciences by the numbers, 2016–2025

Between 2016 and 2025 Kezar Life Sciences reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-56.0M.

On a trailing twelve-month basis to Dec '25, revenue is $0 and net profit $-57.0M.

Borrowings stand at $2.0M, cash from operations was $-52.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -51.8% over five years, and was -80.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Kezar Life Sciences (KZR) — frequently asked questions